Epcoritamab

monoclonal antibody

Identifier: CI-DRUG-00000759
Entity page: /drug/epcoritamab ↗
Edges: 118

Neighbours: 17 cancers4 genes10 trials7 approvals
Drawn: 38 of 38 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Epcoritamab approved for …APPROVED_FOR10 of 7
→ approved for	Follicular Lymphomahematologic_malignancy	supports	FDA ORIG	Follicular Lymphoma	1	Regulatory	openfda	graph →
→ approved for	Diffuse Large B-Cell Lymphomahematologic_malignancy	supports	EMA indication text

Epcoritamab targets …TARGETS4 of 4
→ targets	CD3D	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	CD3G	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	MS4A1	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	CD3E	—	BINDING AGENT	—	1	Curated	chembl	graph →

Epcoritamab targets …TARGETS4 of 4

→ targets

CD3D

—

BINDING AGENT

—

Curated

Epcoritamab investigated for …INVESTIGATED_FOR6 of 6
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	4	Follicular Lymphoma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	2	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	B-Cell Malignant Neoplasmcancer_family	unknown	1	B-Cell Malignant Neoplasm	1	Curated	chembl	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	1	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	1	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →

Epcoritamab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 42show all (up to 200)
→ investigated in trials for	Diffuse Large B-Cell Lymphomahematologic_malignancy 21 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	High Grade B-Cell Lymphoma 12 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High Grade B-Cell Lymphoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Lymphomahematologic_malignancy 11 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Lymphoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Mediastinal Large B-Cell Lymphoma 9 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Mediastinal Large B-Cell Lymphoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 8 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 7 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 6 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoma 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Marginal Zone Lymphoma 5 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Marginal Zone Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Non-Hodgkin Lymphoma 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Non-Hodgkin Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 3b Follicular Lymphoma 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 3b Follicular Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	2	Observed	clinicaltrials	graph →

Epcoritamab studied in …STUDIED_INderived10 of 59show all (up to 200)
→ studied in	NCT06045247Phase 2 · recruiting Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma · 59 trials list this drug (53 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · 59 trials list this drug (53 active)	—	—	Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06672705Phase 1 · recruiting Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders · 59 trials list this drug (53 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07783594Phase 2 · not yet recruiting Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma · 59 trials list this drug (53 active)	—	—	Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06090539Phase 1/Phase 2 · recruiting A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas · 59 trials list this drug (53 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07819214Phase 2 · not yet recruiting Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI · 59 trials list this drug (53 active)	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05201248Phase 1/Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma · 59 trials list this drug (53 active)	—	—	B-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05206357Phase 1 · active not recruiting Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab · 59 trials list this drug (53 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05451810Phase 2 · active not recruiting A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma · 59 trials list this drug (53 active)	—	—	Diffuse Large B-Cell Lymphoma,Classic Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05578976Phase 3 · active not recruiting A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) · 59 trials list this drug (53 active)	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths